June 29, 2020 - Shares of Novavax (NVAX) have been upgraded to buy with a $101 price target at H.C Wainwright. The firm sees the Covid-19 vaccine NVX-CoV2373 potentially doing $400 million in annual sales.
Novavax (NVAX) stock was just $5 in early 2020 but has soared to new heights in the last few months. NVAX has been public for nearly 25 years but has always been a failure. Could this time be different?
Keep an eye on the Lemonade (LMND) IPO coming this week - https://daytradingstockblog.blogspot.com/2020/06/lemonade-lmnd-stock-ipo-ai-bots-replace.html